{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:51:07Z","timestamp":1792813867024,"version":"4.5.0"},"reference-count":76,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J NeuroIntervent Surg"],"accepted":{"date-parts":[[2026,5,22]]},"abstract":"<jats:p>Pediatric neurointerventional procedures are increasingly performed, yet antiplatelet management remains largely empirical or extrapolated from adult practice because of limited pediatric-specific evidence. This guideline provides scenario-based recommendations for antiplatelet therapy in children undergoing neurointerventional procedures; anticoagulant therapy will be addressed separately. Institutional protocols from experienced pediatric neurointerventional specialists were integrated with a comprehensive scoping literature review through an iterative consensus process involving the European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), International Pediatric Stroke Organization (IPSO), Society of NeuroInterventional Surgery (SNIS), and World Federation of Interventional and Therapeutic Neuroradiology (WFITN). Recommendations are organized around common clinical scenarios, including elective and emergency aneurysm treatment and the management of thromboembolic complications. Dosing, administration, and monitoring considerations are provided for aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, and glycoprotein IIb\/IIIa inhibitors, with additional attention to age-dependent pharmacokinetics, renal function, available formulations, and platelet-function testing. These expert-consensus recommendations are intended to support safer and more consistent clinical practice while recognizing the need for individualized clinical judgment and prospective pediatric studies.<\/jats:p>","DOI":"10.1136\/jnis-2026-025420","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:20:22Z","timestamp":1781198422000},"page":"jnis-2026-025420","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["ESMINT-ESNR-IPSO-SNIS-WFITN guidelines on antiplatelet therapy in pediatric neurointervention: practical recommendations and dosing strategies"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-3948","authenticated-orcid":false,"given":"Sophia","family":"Hohenstatt","sequence":"first","affiliation":[{"name":"Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany"},{"name":"Medical Faculty, Heidelberg University, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9236-2356","authenticated-orcid":false,"given":"Lucie","family":"Thibault","sequence":"additional","affiliation":[{"name":"PharmD, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren B","family":"Orbach","sequence":"additional","affiliation":[{"name":"Neurointerventional Radiology, Boston Children\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5885-7259","authenticated-orcid":false,"given":"Steven W","family":"Hetts","sequence":"additional","affiliation":[{"name":"Radiology, UCSF, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shaibani","sequence":"additional","affiliation":[{"name":"Department of Radiology, Neurology, and Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna T","family":"Fifi","sequence":"additional","affiliation":[{"name":"Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-8781","authenticated-orcid":false,"given":"Clemens Maria","family":"Schirmer","sequence":"additional","affiliation":[{"name":"Neurosurgery, Geisinger Health System, Danville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cook Children\u2019s Medical Center, Fort Worth, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus A","family":"M\u00f6hlenbruch","sequence":"additional","affiliation":[{"name":"Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-1578","authenticated-orcid":false,"given":"Adam","family":"Rennie","sequence":"additional","affiliation":[{"name":"Radiology, Great Ormond Street Hospital for Children, London, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026061110201439000_jnis-2026-025420v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.12.016"},{"key":"2026061110201439000_jnis-2026-025420v1.2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12267"},{"key":"2026061110201439000_jnis-2026-025420v1.3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0038-1676375","article-title":"Antiplatelet Therapy Monitoring in Neonates and Children","volume":"45","author":"Huang","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"2026061110201439000_jnis-2026-025420v1.4","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000183"},{"key":"2026061110201439000_jnis-2026-025420v1.5","doi-asserted-by":"publisher","DOI":"10.1177\/1747493018799958"},{"key":"2026061110201439000_jnis-2026-025420v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnis-2022-019844"},{"key":"2026061110201439000_jnis-2026-025420v1.7","unstructured":"ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population . International council for harmonisation of technical requirements for pharmaceuticals for human use. London, UK: European Medicines Agency (EMA), 2018."},{"key":"2026061110201439000_jnis-2026-025420v1.8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/pm-22-11","article-title":"Pharmacokinetics of drugs: newborn perspective","volume":"7","author":"Bansal","year":"2024","journal-title":"Pediatr Med"},{"key":"2026061110201439000_jnis-2026-025420v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2014.143"},{"key":"2026061110201439000_jnis-2026-025420v1.10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/bdd.2052","article-title":"Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions","volume":"38","author":"Nicolas","year":"2017","journal-title":"Biopharm Drug Dispos"},{"key":"2026061110201439000_jnis-2026-025420v1.11","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-19.4.262"},{"key":"2026061110201439000_jnis-2026-025420v1.12","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018010-00002"},{"key":"2026061110201439000_jnis-2026-025420v1.13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/bcp.12741","article-title":"Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future","volume":"80","author":"O\u2019Hara","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2026061110201439000_jnis-2026-025420v1.14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.thromres.2023.03.005","article-title":"Platelet function in neonates and children","volume":"231","author":"Van Den Helm","year":"2023","journal-title":"Thromb Res"},{"key":"2026061110201439000_jnis-2026-025420v1.15","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199021000-00019"},{"key":"2026061110201439000_jnis-2026-025420v1.16","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-01-0047"},{"key":"2026061110201439000_jnis-2026-025420v1.17","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1111\/jth.12372","article-title":"Developmental hemostasis: age-specific differences in the levels of hemostatic proteins","volume":"11","author":"Attard","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2026061110201439000_jnis-2026-025420v1.18","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/jth.14276","article-title":"Antithrombotic therapy management of adult and pediatric cardiac surgery patients","volume":"16","author":"Baumann Kreuziger","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2026061110201439000_jnis-2026-025420v1.19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ijlh.12531","article-title":"Developmental hemostasis: laboratory and clinical implications","volume":"38 Suppl 1","author":"Toulon","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"2026061110201439000_jnis-2026-025420v1.20","article-title":"Formulation Challenges and Strategies to Develop Pediatric Dosage Forms","volume":"9","author":"Malkawi","year":"2022","journal-title":"Children (Basel)"},{"key":"2026061110201439000_jnis-2026-025420v1.21","doi-asserted-by":"crossref","unstructured":"Hohenstatt S , Vollherbst DF , Nguyen TN , et al . The SAFEST Study: Survey on Antiplatelets in Flow Diversion for Aneurysm Endovascular Treatment. SVIN 2024;4. doi:10.1161\/SVIN.124.001464","DOI":"10.1161\/SVIN.124.001464"},{"key":"2026061110201439000_jnis-2026-025420v1.22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/09537104.2018.1513473","article-title":"Flow cytometry for pediatric platelets","volume":"30","author":"Ignatova","year":"2019","journal-title":"Platelets"},{"key":"2026061110201439000_jnis-2026-025420v1.23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MAT.0000000000000768","article-title":"Monitoring of Antiplatelet Therapy in Children on Ventricular Assist Device Support: Comparison of Multiplate and Thromboelastography Platelet Mapping","volume":"65","author":"Ferguson","year":"2019","journal-title":"ASAIO J"},{"key":"2026061110201439000_jnis-2026-025420v1.24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1249081"},{"key":"2026061110201439000_jnis-2026-025420v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12376"},{"key":"2026061110201439000_jnis-2026-025420v1.26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114053","article-title":"Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS ONE"},{"key":"2026061110201439000_jnis-2026-025420v1.27","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.jtcvs.2017.06.031","article-title":"Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery","volume":"154","author":"Emani","year":"2017","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026061110201439000_jnis-2026-025420v1.28","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A4959"},{"key":"2026061110201439000_jnis-2026-025420v1.29","first-page":"610","article-title":"Novel Dosing and Monitoring of Aspirin in Infants With Systemic-to-Pulmonary Artery Shunt Physiology: the SOPRANO Study","volume":"28","author":"Branstetter","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026061110201439000_jnis-2026-025420v1.30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00246-023-03377-6","article-title":"Analysis of Platelet Function Testing in Children Receiving Aspirin for Antiplatelet Effects","volume":"45","author":"Newland","year":"2024","journal-title":"Pediatr Cardiol"},{"key":"2026061110201439000_jnis-2026-025420v1.31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0974-2069.107236","article-title":"Anti-platelet agents in pediatric cardiac practice","volume":"6","author":"Mohanty","year":"2013","journal-title":"Ann Pediatr Cardiol"},{"key":"2026061110201439000_jnis-2026-025420v1.32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1542\/peds.62.5S.867","article-title":"Clinical pharmacokinetics of aspirin","volume":"62","author":"Levy","year":"1978","journal-title":"Pediatrics"},{"key":"2026061110201439000_jnis-2026-025420v1.33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2308"},{"key":"2026061110201439000_jnis-2026-025420v1.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-007-9098-7"},{"key":"2026061110201439000_jnis-2026-025420v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.05.017"},{"key":"2026061110201439000_jnis-2026-025420v1.36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00246-024-03509-6","article-title":"The Effects of Aspirin dose in Children with Congenital and Acquired Heart Disease. Results from the Paediatric Study of Aspirin Efficacy using Diagnostic and Monitoring Tools (PAED-M)","volume":"46","author":"Regan","year":"2025","journal-title":"Pediatr Cardiol"},{"key":"2026061110201439000_jnis-2026-025420v1.37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S1047951121002973","article-title":"Aspirin resistance in infants with shunt-dependent congenital heart disease","volume":"32","author":"Koh","year":"2022","journal-title":"Cardiol Young"},{"key":"2026061110201439000_jnis-2026-025420v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2014.06.016"},{"key":"2026061110201439000_jnis-2026-025420v1.39","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283385420"},{"key":"2026061110201439000_jnis-2026-025420v1.40","doi-asserted-by":"crossref","first-page":"108167","DOI":"10.1016\/j.clineuro.2024.108167","article-title":"Racial differences in P2Y12 inhibitor responsiveness in patients undergoing neuro-endovascular procedures: A cohort from the Middle East","volume":"239","author":"Jebrin","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"key":"2026061110201439000_jnis-2026-025420v1.41","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2526"},{"key":"2026061110201439000_jnis-2026-025420v1.42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.715821"},{"key":"2026061110201439000_jnis-2026-025420v1.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114588"},{"key":"2026061110201439000_jnis-2026-025420v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.12.050"},{"key":"2026061110201439000_jnis-2026-025420v1.45","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090163"},{"key":"2026061110201439000_jnis-2026-025420v1.46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.921502"},{"key":"2026061110201439000_jnis-2026-025420v1.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"2026061110201439000_jnis-2026-025420v1.48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPH.0000000000000291","article-title":"Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study","volume":"37","author":"Styles","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026061110201439000_jnis-2026-025420v1.49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events","volume":"374","author":"Heeney","year":"2016","journal-title":"N Engl J Med"},{"key":"2026061110201439000_jnis-2026-025420v1.50","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/bcp.12042","article-title":"A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity","volume":"75","author":"Jakubowski","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2026061110201439000_jnis-2026-025420v1.51","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1477"},{"key":"2026061110201439000_jnis-2026-025420v1.52","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/ajh.25273","article-title":"A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study","volume":"93","author":"Hsu","year":"2018","journal-title":"Am J Hematol"},{"key":"2026061110201439000_jnis-2026-025420v1.53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014095"},{"key":"2026061110201439000_jnis-2026-025420v1.54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40261-019-00800-w","article-title":"Development Strategy and Relative Bioavailability of a Pediatric Tablet Formulation of Ticagrelor","volume":"39","author":"Niazi","year":"2019","journal-title":"Clin Drug Investig"},{"key":"2026061110201439000_jnis-2026-025420v1.55","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s40262-019-00758-0","article-title":"Population Pharmacokinetics\/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease","volume":"58","author":"Amilon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026061110201439000_jnis-2026-025420v1.56","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28977","article-title":"Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months","volume":"68","author":"Duniva Inusa","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026061110201439000_jnis-2026-025420v1.57","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/19714009241303122","article-title":"Cangrelor use in a pediatric patient with aneurysmal subarachnoid hemorrhage","volume":"38","author":"Russo","year":"2025","journal-title":"Neuroradiol J"},{"key":"2026061110201439000_jnis-2026-025420v1.58","doi-asserted-by":"publisher","DOI":"10.1136\/jnis-2023-020094"},{"key":"2026061110201439000_jnis-2026-025420v1.59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/jth.15141","article-title":"Cangrelor PK\/PD analysis in post-operative neonatal cardiac patients at risk for thrombosis","volume":"19","author":"Vargas","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2026061110201439000_jnis-2026-025420v1.60","first-page":"465","article-title":"P2Y12 Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease","volume":"2","author":"Kaza","year":"2017","journal-title":"JACC: Basic to Translational Science"},{"key":"2026061110201439000_jnis-2026-025420v1.61","first-page":"707","article-title":"Cangrelor Dosing and Monitoring for Prevention of Acute Systemic-to-Pulmonary Artery Shunt Thrombosis in Neonates","volume":"27","author":"Anton-Martin","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026061110201439000_jnis-2026-025420v1.62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/aor.13782","article-title":"Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices","volume":"45","author":"Fahnhorst","year":"2021","journal-title":"Artif Organs"},{"key":"2026061110201439000_jnis-2026-025420v1.63","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2022.01.1316","article-title":"Impact of Cangrelor Use in Children Supported on Paracorporeal Ventricular Assist Devices","volume":"41","author":"Radel","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2026061110201439000_jnis-2026-025420v1.64","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/09537104.2020.1732323","article-title":"Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction","volume":"31","author":"Sirico","year":"2020","journal-title":"Platelets"},{"key":"2026061110201439000_jnis-2026-025420v1.65","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1016\/S0735-1097(23)03745-2","article-title":"CANGRELOR FOR COMPLEX PCI IN A CHILD","volume":"81","author":"Ahuja","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026061110201439000_jnis-2026-025420v1.66","doi-asserted-by":"crossref","unstructured":"Coulibaly NJ , Elgouhari MH , Arshad MH , et al . Cangrelor for neurointerventional procedures: A systematic review. Interv Neuroradiol 2024;15910199241247255. doi:10.1177\/15910199241247255","DOI":"10.1177\/15910199241247255"},{"key":"2026061110201439000_jnis-2026-025420v1.67","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1097\/PCC.0000000000002292","article-title":"Platelet Inhibition With IV Glycoprotein IIb\/IIIa Inhibitor to Prevent Thrombosis in Pediatric Patients Undergoing Aortopulmonary Shunting","volume":"21","author":"Emani","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"2026061110201439000_jnis-2026-025420v1.68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4103\/apc.apc_175_24","article-title":"Eptifibatide bolus dose postductal stenting intervention: A single-center experience","volume":"17","author":"Mehta","year":"2024","journal-title":"Ann Pediatr Cardiol"},{"key":"2026061110201439000_jnis-2026-025420v1.69","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1097\/PCC.0b013e3181fe44a6","article-title":"Endovascular treatment of near-fatal neonatal superior vena cava syndrome","volume":"12","author":"Mack","year":"2011","journal-title":"Pediatr Crit Care Med"},{"key":"2026061110201439000_jnis-2026-025420v1.70","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1017\/S1047951121003474","article-title":"Acute intraprocedural thrombosis during an arterial ductal stenting successfully managed by eptifibatide","volume":"32","author":"Mumtaz","year":"2022","journal-title":"Cardiol Young"},{"key":"2026061110201439000_jnis-2026-025420v1.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808133390704"},{"key":"2026061110201439000_jnis-2026-025420v1.72","doi-asserted-by":"crossref","DOI":"10.25259\/SNI_873_2022","article-title":"Intracranial aneurysms in pediatric population treated with flow diverters: A single-center experience","volume":"13","author":"Santos-Franco","year":"2022","journal-title":"Surg Neurol Int"},{"key":"2026061110201439000_jnis-2026-025420v1.73","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00381-016-3311-z","article-title":"Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature","volume":"33","author":"Cobb","year":"2017","journal-title":"Childs Nerv Syst"},{"key":"2026061110201439000_jnis-2026-025420v1.74","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000209620.44017.97"},{"key":"2026061110201439000_jnis-2026-025420v1.75","first-page":"e359","article-title":"2025 ACC\/AHA Clinical Practice Guidelines Core Principles and Development Process: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"152","author":"Otto","year":"2025","journal-title":"Circulation"},{"key":"2026061110201439000_jnis-2026-025420v1.76","unstructured":"Committee for Practice Guidelines of the European Society of Cardiology . Recommendations for guidelines production: A Document for Task Force Members Responsible for Producing and Updating ESC Guidelines. European Society of Cardiology, 2010."}],"container-title":["Journal of NeuroInterventional Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnis-2026-025420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:20:30Z","timestamp":1781198430000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnis.bmj.com\/lookup\/doi\/10.1136\/jnis-2026-025420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":76,"alternative-id":["10.1136\/jnis-2026-025420"],"URL":"https:\/\/doi.org\/10.1136\/jnis-2026-025420","relation":{},"ISSN":["1759-8478","1759-8486"],"issn-type":[{"value":"1759-8478","type":"print"},{"value":"1759-8486","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}